Abstract
The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 10-18 |
| Number of pages | 9 |
| Journal | Journal of Cellular Physiology |
| Volume | 205 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Oct 2005 |
Fingerprint
ASJC Scopus subject areas
- Clinical Biochemistry
- Cell Biology
- Physiology
Cite this
HER-2 : A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. / Pupa, Serenella M.; Tagliabue, Elda; Ménard, Sylvie; Anichini, Andrea.
In: Journal of Cellular Physiology, Vol. 205, No. 1, 10.2005, p. 10-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HER-2
T2 - A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
AU - Pupa, Serenella M.
AU - Tagliabue, Elda
AU - Ménard, Sylvie
AU - Anichini, Andrea
PY - 2005/10
Y1 - 2005/10
N2 - The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.
AB - The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=24344474832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24344474832&partnerID=8YFLogxK
U2 - 10.1002/jcp.20387
DO - 10.1002/jcp.20387
M3 - Article
VL - 205
SP - 10
EP - 18
JO - Journal of cellular and comparative physiology
JF - Journal of cellular and comparative physiology
SN - 0021-9541
IS - 1
ER -